CDK4 and breast cancer: Since T-DXd has made a breakthrough in HER2-positive breast cancer, anti-HER2 ADC combined with CDK4/6 inhibitor and endocrine therapy may be the future exploring direction of HR-positive/HER2-positive breast cancer.